Table 1 Main characteristics and clinical data of HIV+ and HIV− patients with non-Hodgkin lymphoma receiving HDC and ASCT.

From: B- and T-lymphocyte number and function in HIV+/HIV− lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation

 

HIV+ patients (#=11)a

HIV− patients (#=9)

number (%)b

number (%)

Sex (males)

11 (100%)

5 (56%)*

Age: median years (range)

46 (29–54)

51 (27–70)

Detectable HIV-viral load at enrolment

1 (9%)c

na

Hepatitis B surface antigen positive

0 (0%)

1 (11%)

Hepatitis C virus positive

3 (27%)

0 (0%)

Epstein Barr virus positive

4d

1

Histology

 DLBCL

5 (45%)

8 (89%)

 Plasmablastic lymphoma

4 (36%)

0 (0%)

 Anaplastic large cell lymphoma ALK-negative

1 (9%)

0 (0%)

 Intermediate BL/DLBCL

1 (9%)

0 (0%)

 High grade B-cell lymphoma, unclassified

0 (0%)

1 (11%)

Ann-Arbor classification

 Stage I–II

1 (9%)

2 (22%)

 Stage III–IV

10 (91%)

7 (78%)

Disease status

 1st complete remission

3 (27%)

4 (44%)

 2nd complete remission

1 (9%)

1 (11%)

 1st partial remission

6 (55%)

4 (44%)

 chemosensitive relapse

1 (9%)

0 (0%)

Previous lines of therapies:

 1

7 (64%)

7 (78%)

 2

3 (27%)

2 (22%)

 3

1 (9%)

0 (0%)

Rituximab treatment before ASCT

5 (45%)

9 (100%)*

Conditioning regimen:

 BEAMe

10 (91%)

9 (100%)

 Carmustine-thiotepaf

1 (9%)

0 (0%)

T0g versus the last day of induction chemotherapy: median days (range)

55 (40–212)

50 (36–132)

T0g versus the last rituximab administration: median days (range)

98 (43–107)

73 (43–139)

Mobilized CD34+cells: median × 106 (range)

5.8 (2.65–12.9)

16.3 (6.4–20.7)*

Infused CD34+cells: median × 106/Kg of body weight (range)

5.8 (2.65–9.5)

6.9 (4.4–9.4)

Neutrophil engraftment: median days (range)

10 (9–12)

9 (8–11)

Late onset neutropenia

2 (18%)

2 (22%)

Platelet engraftment: median days (range)

13 (10–16)

12 (10–16)

Radiotherapy after ASCT

6 (55%)

3 (33%)

  1. Abbreviations: na, not applicable; ns, not significant; ALK, anaplastic lymphoma kinase; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma.
  2. *P < 0.05 (P-value calculations were done by the Fisher exact test for categorical variables and unpaired t test for continuous variables).
  3. aThree patients were intravenous drug users, 4 were men who had sex with men and 4 were heterosexual. Two patients had an AIDS-defining condition other than NHL: 1 cutaneous Kaposi sarcoma and 1 extrapulmonary tuberculosis;
  4. bunit of measure is count (percentage) unless differently specified;
  5. cviremia: 2.374 copies/mL;
  6. dEBV was detected by using immunohistochemistry only in 4 out 7 HIV+ and in 1 out 3 HIV− patients analysed;
  7. ecarmustine 300 mg/m2, cytarabine 800 mg/m2, etoposide 800 mg/m2, and melphalan 140 mg/m2;
  8. fcarmustine 400 mg/m2, thiotepa 20 mg/Kg;
  9. gT0: the day preceding the conditioning regimen.
Back to article page